Company news
BioSenic news in 2024
BioSenic's news releases, calls and decks from 2024, newest first.
BioSenic: Medsenic, a subsidiary of BioSenic, has signed a conditional letter of intent that could secure funding to cover part of the costs for its clinical trial on chronic graft versus host disease
December 14, 2024
BioSenic provides third quarter 2024 Business Update
October 28, 2024
Carole Nicco steps down from her roles as Chief Scientific and Operations Officer of BioSenic to focus on the subsidiary Medsenic SAS
October 14, 2024
Transparency notification received from ABO Infinium Americas OpCo LTD.
October 7, 2024
Transparency notification received from ABO Infinium Americas OpCo LTD.
October 7, 2024
BioSenic announces that it has started to look for new assets, the securing of its financing for the coming months by means of an amendment to its convertible bond contract, a change to the composition of its board of directors
September 30, 2024
Half-year Financial Report H1 2024
September 30, 2024
Decks in 2024
- Investor Presentation (January 2024)
Investor deck · 24 slides · January 2024